Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CELU

CELU - Celularity Inc. Stock Price, Fair Value and News

3.25USD+0.01 (+0.31%)Market Closed

Market Summary

CELU
USD3.25+0.01
Market Closed
0.31%

CELU Stock Price

View Fullscreen

CELU RSI Chart

CELU Valuation

Market Cap

627.9M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

46.26

EV/EBITDA

-0.56

Price/Free Cashflow

-10.5

CELU Price/Sales (Trailing)

CELU Profitability

EBT Margin

-1226.64%

Return on Equity

-599.76%

Return on Assets

-115.41%

Free Cashflow Yield

-9.53%

CELU Fundamentals

CELU Revenue

Revenue (TTM)

14.8M

Rev. Growth (Yr)

-8.44%

Rev. Growth (Qtr)

28.86%

CELU Earnings

Earnings (TTM)

-181.4M

Earnings Growth (Yr)

-2.1K%

Earnings Growth (Qtr)

-95.78%

Breaking Down CELU Revenue

Last 7 days

-0.3%

Last 30 days

12.1%

Last 90 days

-43.2%

Trailing 12 Months

303.1%

How does CELU drawdown profile look like?

CELU Financial Health

Current Ratio

0.19

Debt/Equity

0.56

Debt/Cashflow

-3.75

CELU Investor Care

Shares Dilution (1Y)

30.12%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202316.0M15.1M14.8M0
202224.6M25.2M18.7M18.0M
202113.5M12.5M19.7M21.3M
202018.9M016.6M14.3M
201900021.1M

Tracking the Latest Insider Buys and Sells of Celularity Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 13, 2024
fletcher kyle
sold (taxes)
-82.2
4.11
-20.00
see remarks
Apr 13, 2024
brigido stephen
sold (taxes)
-1,101
4.11
-268
pres, functional regeneration
Apr 13, 2024
beers david c
sold (taxes)
-1,479
4.11
-360
chief financial officer
Apr 13, 2024
haines john r
sold (taxes)
-2,367
4.11
-576
see remarks
Apr 13, 2024
hariri robert j
sold (taxes)
-4,742
4.11
-1,154
chief executive officer
Mar 15, 2024
fletcher kyle
sold (taxes)
-3,504
5.68
-617
see remarks
Feb 17, 2024
kilcoyne adrian
sold (taxes)
-22,898
0.434
-52,762
chief medical officer
Feb 17, 2024
haines john r
sold (taxes)
-30,531
0.434
-70,350
see remarks
Feb 17, 2024
beers david c
sold (taxes)
-19,082
0.434
-43,968
chief financial officer
Feb 17, 2024
brigido stephen
sold (taxes)
-14,200
0.434
-32,720
pres, functional regeneration

1–10 of 50

Which funds bought or sold CELU recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
1,000
1,000
-%
May 15, 2024
STATE STREET CORP
sold off
-100
-61,677
-
-%
May 15, 2024
STATE STREET CORP
new
-
130,384
130,384
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-12,693
-
-%
May 15, 2024
MORGAN STANLEY
new
-
46,286
46,286
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-1,100
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
new
-
12,755
12,755
-%
May 15, 2024
CITADEL ADVISORS LLC
sold off
-100
-580
-
-%
May 15, 2024
Royal Bank of Canada
new
-
118,000
118,000
-%
May 15, 2024
Royal Bank of Canada
sold off
-100
-56,000
-
-%

1–10 of 47

Are Funds Buying or Selling CELU?

Are funds buying CELU calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CELU
No. of Funds

Unveiling Celularity Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 15, 2024
dragasac ltd
27.6%
6,335,630
SC 13D/A
Feb 08, 2024
united therapeutics corp
4.11%
7,968,848
SC 13G/A
Jan 17, 2024
dragasac ltd
27.8%
63,356,326
SC 13D/A
Oct 05, 2023
sorrento therapeutics, inc.
2.6%
5,050,427
SC 13G/A
Jun 22, 2023
dragasac ltd
19.6%
36,592,597
SC 13D/A
Feb 13, 2023
starr international co inc
10.54%
15,281,389
SC 13G/A
Feb 13, 2023
c v starr & co inc
5.27%
7,640,693
SC 13G
Feb 06, 2023
united therapeutics corp
5.50%
7,968,848
SC 13G/A
Feb 03, 2023
united therapeutics corp
6.51%
7,968,848
SC 13G
Feb 04, 2022
weiss asset management lp
0.00%
0
SC 13G/A

Recent SEC filings of Celularity Inc.

View All Filings
Date Filed Form Type Document
May 24, 2024
8-K
Current Report
May 21, 2024
8-K
Current Report
May 15, 2024
NT 10-Q
NT 10-Q
Apr 22, 2024
8-K
Current Report
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 01, 2024
NT 10-K
NT 10-K

Peers (Alternatives to Celularity Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
17.55% 15.42%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
6.10% -19.49%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.03% -10.77%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
4.06% -3.24%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
16.82% -26.89%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
20.98% 97.26%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
19.55% 492.49%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-16.55% 51.92%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Celularity Inc. News

Latest updates
MarketBeat03 Jun 202404:51 am
Yahoo Movies UK02 Jun 202410:30 am

Celularity Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q12019Q4
Revenue28.9%3,786,0002,938,0003,935,0004,129,0004,135,0003,776,0005,935,0004,856,00010,622,0003,197,0002,660,0003,243,0003,355,0004,208,000-
Operating Expenses----------1,538,68147,055,000153,063,643208,30525,204,000284,958,625
  S&GA Expenses-16.2%10,748,00012,826,00013,934,00019,080,00014,907,00015,574,00016,460,00013,208,00021,644,00028,863,0007,626,0005,973,0008,327,0009,450,000-
  R&D Expenses-39.8%5,182,0008,604,00016,951,00010,990,00020,351,00025,349,00021,673,00024,687,00023,765,00022,911,00016,990,00013,924,00011,217,00011,762,000-
EBITDA Margin-140.6%-11.62-4.831.421.32-0.241.61-2.93-4.27-7.40-19.43-14.19-10.02---
Interest Expenses-100.0%-822,000251,000-------752,000----
Income Taxes----13,000-17,00017,000-9,000-16,35043,700--4,699,41515,0004,653,000-
Earnings Before Taxes-95.8%-93,876,000-47,949,000-64,017,00024,447,0004,782,00047,843,000-62,867,000-4,020,00049,938,000-64,477,000-81,539,000-57,890,496-46,310,000-34,853,000-270,216,413
EBT Margin-124.4%-12.27-5.470.820.79-0.761.23-3.31-4.69-7.81-20.09-14.80-10.59-22.73-15.59-
Net Income-95.8%-93,876,000-47,949,000-64,017,00024,434,0004,799,00047,826,000-62,867,000-4,040,00049,938,000-64,477,000-81,539,0003,910,000-46,325,000-30,200,000-213,636,706
Net Income Margin-124.4%-12.27-5.470.820.79-0.761.23-3.31-4.69-4.67-15.13-19.42-14.58-26.62-12.46-
Free Cashflow22.7%-8,550,000-11,058,000-15,204,000-30,364,000-39,283,000-37,758,000-35,707,000-34,348,000-35,884,000-19,508,000-26,559,000-26,203,000-49,416,990-29,251,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-36.2%157246362401437429434414448128405431292292293521291290-
  Current Assets-8.5%16.0018.0025.0034.0063.0075.0076.0059.0091.000.0043.0072.001.001.001.0037.001.001.000.00
    Cash Equivalents-91.1%0.003.003.0014.0057.0053.0063.0052.0087.0023.0038.0070.0096.001.0011744.001.001.0023.00
  Inventory-14.0%5.006.005.005.005.0025.0015.0010.006.00-5.004.00---3.00---
  Net PPE-2.7%71.0073.0074.0076.0077.0078.0078.0091.0091.00-90.0090.00---66.00---
  Goodwill-91.8%7.0090.0090.00120123123123123123-123123---127---
Liabilities-0.8%12712820720227327934431535247.0046741234.0023.0012.0038424.0021.00-
  Current Liabilities30.3%85.0065.0066.0062.0069.0033.0026.0026.0029.007.0025.0027.000.000.000.0021.000.000.000.00
  Short Term Borrowings-16.7%14.0017.0031.0038.0039.00--------------
  Long Term Debt-100.0%-17.005.00----------------
Shareholder's Equity-74.5%30.0011915619916415090.0099.0096.00--5.005.005.005.005.005.005.000.00
  Retained Earnings-12.4%-851-757-709-645-669-674-722-663-659-47.41-645-563-13.80-3.260.00-3554.00-0.480.00
  Additional Paid-In Capital0.6%879874862844834825812763756-33.0032.0014.002.00-0.3428.001.004.000.00
Shares Outstanding7.1%19418116514913813513012410624.0024.0019.0018.0026.0024.0024.00---
Float------227---128---293---297-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations24.5%-8,322-11,027-14,995-29,585-37,720-36,318-34,253-32,045-34,771-18,200-25,080-16,831-45,58724,648-25,422-65,918-679-194-676*-543*-
Cashflow From Investing-635.5%-228-31.00-3,209-779-1,563-1,440-1,454-2,303-1,113-1,008-1,479-9,372-4,0164,403-3,829------
Cashflow From Financing2.3%5,7395,61012,7591,68543,93927,71946,495-1,014100,4034,015-4,842-317--102,550-169,585-288,844-5.1525.00-
  Buy Backs-------75.00-11.00--------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CELU Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net revenues    
Total revenues$ 3,786,000$ 4,135,000$ 10,659,000$ 13,846,000
Cost of revenues (excluding amortization of acquired intangible assets)    
Research and development5,182,00020,351,00030,737,00067,373,000
Software cease-use costs243,000 24,161,000 
Selling, general and administrative10,748,00014,907,00037,508,00046,941,000
Change in fair value of contingent consideration liability0(33,243,000)(104,339,000)(73,441,000)
Goodwill impairment82,714,0000112,347,0000
IPR&D impairment00107,800,0000
Amortization of acquired intangible assets553,000553,0001,640,0001,640,000
Total operating expenses103,042,0009,781,000216,261,00056,931,000
Loss from operations(99,256,000)(5,646,000)(205,602,000)(43,085,000)
Other income (expense):    
Interest income23,000108,000205,000155,000
Interest expense(971,000)0(2,352,000)0
Change in fair value of warrant liabilities5,187,0009,333,0006,788,00031,613,000
Change in fair value of debt2,003,000(291,000)(354,000)(291,000)
Other income (expense), net(862,000)1,278,000(4,527,000)1,366,000
Total other income (expense)5,380,00010,428,000(240,000)32,843,000
(Loss) income before income taxes(93,876,000)4,782,000(205,842,000)(10,242,000)
Income tax benefit0(17,000)00
Net (loss) income(93,876,000)4,799,000(205,842,000)(10,242,000)
Change in fair value of debt due to change in credit risk, net of tax0236,0002,541,000236,000
Other comprehensive income0236,0002,541,000236,000
Comprehensive (loss) income$ (93,876,000)$ 5,035,000$ (203,301,000)$ (10,006,000)
Net (loss) income per share - basic$ (0.5)$ 0.03$ (1.19)$ (0.07)
Weighted average shares outstanding - basic188,317,262142,676,953173,536,134137,787,645
Net (loss) income per share - diluted$ (0.5)$ 0.03$ (1.19)$ (0.07)
Weighted average shares outstanding - diluted188,317,262150,546,268173,536,134137,787,645
Product Sales and Rentals    
Net revenues    
Total revenues$ 1,684,000$ 1,041,000$ 3,633,000$ 2,920,000
Cost of revenues (excluding amortization of acquired intangible assets)    
Cost of revenues557,000812,0001,486,0001,711,000
Services    
Net revenues    
Total revenues1,427,0001,405,0004,062,0004,061,000
Cost of revenues (excluding amortization of acquired intangible assets)    
Cost of revenues398,000899,0001,355,0003,112,000
Licenses, Royalties and Other    
Net revenues    
Total revenues675,0001,689,0002,964,0006,865,000
Cost of revenues (excluding amortization of acquired intangible assets)    
Cost of revenues$ 2,647,000$ 5,502,000$ 3,566,000$ 9,595,000

CELU Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 273$ 13,966
Accounts receivable, net of allowance of $2,188 and $1,789 as of September 30, 2023 and December 31, 2022, respectively4,1144,452
Notes receivable2,0722,514
Inventory4,9345,308
Prepaid expenses and other current assets5,1057,262
Total current assets16,49833,502
Property and equipment, net70,64775,655
Goodwill7,347119,694
Intangible assets, net11,554120,994
Right-of-use assets - operating leases11,03913,060
Restricted cash14,82514,836
Inventory, net of current portion24,92822,949
Other long-term assets354376
Total assets157,192401,066
Current liabilities:  
Accounts payable12,9315,810
Accrued expenses and other current liabilities10,2399,069
Accrued R&D software24,0007,333
Short-term debt ($14,006 at fair value and $16,623 unpaid principal balance at September 30, 2023)14,00637,603
Other short-term debt2,032 
Other short-term debt - related party1,017 
Short-term debt - related parties17,949 
Deferred revenue2,4582,273
Total current liabilities84,63262,088
Deferred revenue, net of current portion3,0992,219
Acquisition-related contingent consideration1,606105,945
Noncurrent lease liabilities - operating26,07427,985
Noncurrent accrued R&D software7,494 
Warrant liabilities3,7353,598
Deferred income tax liabilities99
Other liabilities296321
Total liabilities126,945202,165
Commitments and Contingencies (Note 9)
Stockholders’ equity  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 730,000,000 shares authorized, 193,659,133 issued and outstanding as of September 30, 2023; 730,000,000 shares authorized, 148,921,187 issued and outstanding as of December 31, 20221915
Additional paid-in capital879,171844,373
Accumulated other comprehensive income2,3959
Accumulated deficit(851,338)(645,496)
Total stockholders’ equity30,247198,901
Total liabilities and stockholders' equity$ 157,192$ 401,066
CELU
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
 CEO
 WEBSITEcelularity.com
 INDUSTRYBiotechnology
 EMPLOYEES225

Celularity Inc. Frequently Asked Questions


What is the ticker symbol for Celularity Inc.? What does CELU stand for in stocks?

CELU is the stock ticker symbol of Celularity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celularity Inc. (CELU)?

As of Wed Jun 12 2024, market cap of Celularity Inc. is 627.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELU stock?

You can check CELU's fair value in chart for subscribers.

What is the fair value of CELU stock?

You can check CELU's fair value in chart for subscribers. The fair value of Celularity Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celularity Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celularity Inc. a good stock to buy?

The fair value guage provides a quick view whether CELU is over valued or under valued. Whether Celularity Inc. is cheap or expensive depends on the assumptions which impact Celularity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELU.

What is Celularity Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, CELU's PE ratio (Price to Earnings) is -3.77 and Price to Sales (PS) ratio is 46.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CELU PE ratio will change depending on the future growth rate expectations of investors.